Vmbook Online ordering

Celator Pharmaceuticals Inc

Celator Pharmaceuticals Inc was a public company based in the United States that focused on the development and commercialization of therapies for cancer treatments. The company's most advanced product candidate was CPX-351, a novel liposomal formulation of cytarabine and daunorubicin, which was being developed for the treatment of acute myeloid leukemia (AML) and other cancers.

Celator Pharmaceuticals was listed on the NASDAQ stock exchange under the ticker symbol "CPXX." However, it's important to note that the company is no longer trading on the NASDAQ as it was acquired by Jazz Pharmaceuticals plc in June 2016 for approximately $1.5 billion.

After the acquisition, Celator's shares were delisted from the NASDAQ, and shareholders received a cash payment for each share they owned. As a result, Celator Pharmaceuticals Inc. is no longer a publicly traded company.